SCYNEXIS

Q2 2022 Earnings Call

August 15, 2022

Forward Looking Statement

This presentation has been prepared by SCYNEXIS, Inc. (“we,” “us,” our,” SCYNEXIS,” or the “Company”) and is made for informational purposes only. The information includes forward-looking statements based on current expectations, including statements concerning our financial outlook for the future, leadership's expectations for our future financial and operational performance, as well as our business strategy. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Please refer to our filings with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, including in each case under the caption "Risk Factors," and in other documents subsequently filed with or furnished to the Securities and Exchange Commission. All forward-looking statements speak only as of today, August 15, 2022. SCYNEXIS undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. The information in this presentation is not intended for promotional purposes and not sufficient for prescribing decisions.

Agenda

Welcome & Opening Remarks	Debbie Etchison
Q2 2022 Overview	Marco Taglietti, M.D.
Commercial Progress	Christine Coyne
Pipeline Update	David Angulo, M.D.
Financial Update	Larry R. Hoffman
Conclusion	Marco Taglietti, M.D.
Q&A	

SCYNEXIS

Marco Taglietti, M.D.

President and CEO

Q2 2022 Overview

Making Ibrexafungerp a Successful Antifungal Franchise

ibrexafungerp



First in class antifungal
Broad spectrum
Oral and IV

June 2021
FDA approval of BREXAFEMME

June 2022
RVVC regulatory submission

Nov. 30, 2022
Potential FDA approval in RVVC

H1 2024
MARIO Invasive candidiasis & FURI/CARES regulatory submissions

H2 2024
Potential approval of stepdown therapy in invasive candidiasis and resistant/refractory hospital infections

2025 and beyond

$700M-$800M Potential Antifungal Franchise

2021 | 2022 | 2023 | 2024 | 2025+

Corporate Update – Recent Accomplishments

R&D

- RVVC sNDA filing accepted and PDUFA set for November 30, 2022
- Phase 3 CANDLE study met its primary and secondary endpoints, along with positive nested sub-study results
- Initiated Phase 3 VANQUISH study
- MARIO enrollment has begun

Commercial

- Growth in BREXAFEMME adoption
- Expanded coverage to ~60% commercial lives covered to date
- 5,141 Rx/~ $1.3 million in Q2 2022 net sales revenue
- Preparing for RVVC anticipated label expansion

Corporate

- Ended Q2 2022 with $118.7 million cash balance
- Raised $45 million in Q2 2022 with cash runway into Q1 2024
- Keep building broad antifungal franchise
- Pursue international partnerships

SCYNEXIS

Christine Coyne

Chief Commercial Officer

Commercial Progress

Sharper Execution Across All BREXAFEMME Key Stakeholders

- Prescribers
- Payers
- Patients

(1) BREXAFEMME Prescribing Information. SCYNEXIS, Inc.; 2021. (2) Data on File. SCYNEXIS, Inc., Jersey City, NJ
Source: ATU Market Research Conducted post launch in Q4 2021

Expansion of BREXAFEMME Prescribers Continued in Q2

Prescriber Growth Metrics

+25% Q2 2022 vs. Q1 2022



- Increase in both new and repeat BREXAFEMME prescribers in Q2 2022

Source: IQVIA

BREXAFEMME Continued to Show Growth in Q2

TRx Growth Metrics

+29% Q2 2022 vs. Q1 2022

BREXAFEMME Q2 Monthly TRx Volume



- BREXAFEMME TRx volume grew due to several factors including more effective field execution paired with our new HCP marketing campaign
- Monthly growth in BREXAFEMME prescribing behavior came from adding new prescribers & broader adoption among repeat prescribers

Source: IQVIA

BREXAFEMME Secured Additional Formulary Coverage in Q2

Coverage Growth Metrics
Commercial Lives

+17% Q2 2022 vs. Q1 2022

BREXAFEMME Covered Lives - Commercial



- Over 109 million (60%) of commercially-insured lives are covered for BREXAFEMME as of Q2 2022
- Large PBM's and payers have been responsive to the high unmet need and clinical value of the first non-azole therapy to treat vaginal yeast infections

Source: MMIT

A Modern Marketing Approach Targeting HCPs + Patients



New ‘Say No More’ HCP and patient campaign debuted at ACOG in May

Targeted patient activation advertising launched in June with tactics across multiple channels including print and digital, all driving patients to ask their HCP for BREXAFEMME

Executing additional, exciting new patient programs in Q3 that will continue empowering women

Continued Momentum Entering the Second Half of 2022

OPTIMIZED SALES FORCE EXECUTION

FOCUS ON HIGH-VALUE HCPS

PATIENT ACTIVATION

INCREASING BASE OF PRESCRIBERS

SCYNEXIS

David Angulo, M.D.

Chief Medical Officer

R&D Pipeline Update

Expansion of the VVC Franchise

sNDA submission for prevention of recurrent VVC was accepted by the FDA

- Priority review granted and given a target regulatory decision date of November 30, 2022
- sNDA was based on the positive Phase 3 CANDLE study, reporting:

Clinical Success
(i.e., no recurrences, not even suspected ones at TOC, Week 24) achieved by

65.4% of patients receiving ibrexafungerp (p=0.02 vs. placebo)

No mycologically proven Recurrence (at TOC, Week 24) achieved by

70.8% of patients receiving ibrexafungerp (p=0.02 vs. placebo)

If approved for this second indication, BREXAFEMME would be the first and only product approved in the U.S. for both:

the **treatment of vulvovaginal** candidiasis (VVC) and

the **prevention of RVVC** .

Activity of Ibrexafungerp in VVC Fluconazole Failures

The **CANDLE open-label sub-study** enrolled 24 patients who failed to respond to an initial three-doses of fluconazole given over seven days.

One Day Treatment IBX 300mg BID	VSS ≥3 after Fluconazole (N=24) n (%)	VSS ≥3 and + culture after Fluconazole (N=10) n (%)
Clinical Success (50% reduction in VSS from Baseline)	17 (71%)	8 (80%)
Clinical Improvement (VSS≤1) at TOC at Day 11	14 (58%)	7 (70%)

- **VANQUISH study**, Phase 3b, open label, evaluating ibrexafungerp in subjects with complicated VVC who have failed prior fluconazole therapy
  - Enrollment ongoing
  - 150 subject planned from 25 centers in the US
  - Data anticipated in 2nd Half of 2024

Oral Ibrexafungerp to Address Multiple Unmet Needs in the Hospital Setting



MARIO
Phase 3, randomized, **oral step-down** trial in Invasive Candidiasis

- Start-up process ongoing
- ~70 sites planned globally
- 10 sites already initiated (United States and South Africa) and enrollment has begun.

SCYNEXIS

Larry Hoffman

Interim Chief Financial Officer

Financial Update

2022 Q2 Financial Summary

Item	Q2 2022	Q2 2021	Highlights/Comments
Net Product Revenue	$1.3	$0.0	BREXAFEMME was launched in Q3 2021. No product revenues were recorded in Q2 2021.
R&D Expenses	$7.1	$4.7	Increase is due the initiation of the MARIO study and its hospital program
SG&A Expenses	$15.8	$12.8	Continued support for the marketing and sales of BREXAFEMME
Cash and Cash Equivalents	$118.7	$112.4*	Cash runway into Q1 2024

$ Millions

* Cash and Cash Equivalents were $104.5 on December 31, 2021

Key Takeaways/Conclusion

- Ibrexafungerp is a **unique systemic antifungal** with great potential in both community and hospital settings to be a successful, durable and profitable antifungal franchise
- **Treatment of VVC is the first of multiple potential indications** for ibrexafungerp. The next one is the prevention of recurrent VVC with anticipated FDA approval at the PDUFA date of November 30, 2022
- Potential approval for **first hospital indication is expected at the end of 2024** as an oral step-down therapy for invasive candidiasis
- With **exclusivity protection until 2035**, ibrexafungerp is expected to become a significant, **long-lasting antifungal franchise** with potential combined peak sales of $700M to $800M (Community + Hospital indications)
- Funds and resources to market BREXAFEMME, continue the hospital clinical development program and advance label expansion, with a **cash runway into Q1 2024**

Q&A

SCYNEXIS